

Iron status in a representative sample of US pregnant women is not associated with pre-pregnancy BMI: results from the NHANES (1999-2010) study

Mihaela A. Ciulei¹, Kelly Gallagher², Djibril Ba³, Celeste Beck¹, Ruth A. Pobee⁴, Alison D. Gernand¹, Rachel E. Walker^{1*}

¹Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, United States of America

²Ross and Carol Nese College of Nursing, The Pennsylvania State University, University Park, Pennsylvania, United States of America

³Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, United States of America

⁴Department of Emergency Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America

* Corresponding author:

E-mail: rew5009@psu.edu (REW)

Abstract

Iron deficiency in pregnancy is related to many poor health outcomes, including anemia and low birth weight. A small number of previous studies have identified maternal body mass index (BMI) as potential risk factors for poor iron status. Our objective was to examine the association between pre-pregnancy BMI and iron status in a nationally representative sample of US adult women. We used data from the National Health and Nutrition Examination Survey (NHANES; 1999-2010) for pregnant women ages 18-49 years (n=1156). BMI (kg/m²) was calculated using pre-pregnancy weight (self-reported) and height (measured at examination). Iron deficiency (ID) was defined as total body iron (calculated from serum ferritin and transferrin receptor using Cook's equation) < 0 mg/kg and anemia as hemoglobin < 11 g/dL. Associations were examined using weighted Poisson regression models, adjusted for confounders (age, race/ethnicity, education, family income, and trimester). Approximately 14% of pregnant women had ID and 8% had anemia in this sample. There were no differences in the prevalence of ID or anemia in women with pre-pregnancy overweight and obesity (ID: overweight, adjusted prevalence ratio (PR)=1.28, 95%CI: 0.89-1.83; obesity, PR=0.75, 95%CI: 0.39-1.45; anemia: overweight, PR=1.08, 95%CI: 0.53-2.19; obesity, PR=0.99, 95%CI: 0.49-2.01) compared to women with a normal BMI. Findings from these US nationally representative data indicate that iron status in pregnancy does not differ by pre-pregnancy BMI. Since iron deficiency during pregnancy remains a significant public health concern, NHANES should consider measuring current iron status in upcoming cycles.

Introduction

During pregnancy, iron deficiency (ID) increases the risk of anemia, low birth weight, and infant mortality, while pre-pregnancy obesity increases the risk of Cesarean section, gestational diabetes, and failure to initiate breastfeeding¹⁻⁴, among other outcomes. Both ID and obesity are common in women of reproductive age in the US, especially in populations of minority race and ethnicity^{5,6}.

The prevalence of ID increases from about 10% in non-pregnant women of reproductive age to about 16-25% during pregnancy due to blood volume expansion and the increased iron needs to meet fetal and placental demand⁷⁻¹⁰, making it a significant public health concern. The severity of ID increases with higher parity^{7,8,11} and across gestation^{12,13}. Therefore, pregnancy is a critical period for managing iron status in women of reproductive age. Based on data from the National Health and Nutrition Examination Survey (NHANES) in the US, 18% of pregnant women suffer from ID defined by total body iron⁹. However, these data are over 10 years old since NHANES has not collected biomarkers of functional and circulating iron status combined with gestational age data since 2010.

Similarly, obesity is growing in prevalence in the US population in general, including in women of reproductive age. Based on a recent analysis of national data, the prevalence of obesity in women of reproductive age was 29% in 2019⁶. Some prior studies have suggested that women with obesity are especially vulnerable to the development of ID due to alterations in metabolism and inflammatory signaling^{14,15}. A prior review article indicated that pre-pregnancy obesity and overweight pose a risk for ID and ID with anemia (IDA) during pregnancy¹⁶. However, obesity is highly confounded by a number of demographic factors at a population level, making it imperative to conduct nation-wide investigations that can adjust for

socioeconomic variation. Given the high prevalence of pre-pregnancy obesity in the US⁶ and the importance of iron to promote a healthy pregnancy, a better understanding of the relationship between these factors on a national level could help identify women at higher risk of ID.

Although there are previous studies in the US showing an association between obesity and iron status^{17,18}, to our knowledge, there are no studies examining iron status and body mass index (BMI) in a US nationally representative sample of pregnant women. Previous studies were performed with a small sample size¹⁷, in other nations^{19–22}, or in adolescents alone¹⁸.

In this study, our objective was to examine iron status by pre-pregnancy BMI category in a nationally representative sample of pregnant women in the US. Based on previous studies, we hypothesized first, that women with pre-pregnancy overweight or obesity would have higher rates of ID, anemia, and IDA during pregnancy compared to women with normal weight.

Methods

Study population

We conducted a cross-sectional analysis of maternal pre-pregnancy BMI and iron status using data collected in the NHANES study (<https://www.cdc.gov/nchs/nhanes/index.htm>). We selected the 1999-2010 cycles because they contain data on measured iron status biomarkers in addition to pregnancy status, gestational age, and self-reported pre-pregnancy weight. Additionally, these years oversampled pregnant women. In the 12 years (1999-2010; 6 cycles) that we selected, there were 62,160 participants, of which 19,569 were between the ages of 18-49 years. Next, we restricted the dataset to include only pregnant women (n=1,414) with positive survey sampling weights (n_missing=76), which resulted in a sample size of 1,338. We further restricted the dataset to include complete observations for measured height (n_missing=6), self-reported pre-pregnancy weight (n_missing=23), and iron and inflammation biomarkers

(n_missing=153). Therefore, the final analytic sample consisted of 1,156 participants. The original NHANES protocol was approved by the National Center for Health Statistics' Research Ethics Review Board ²³, and we used only data publicly available for download.

Iron and acute inflammation biomarkers

To characterize iron and inflammation status, NHANES collected maternal venous blood. Hemoglobin (Hb) was measured in whole blood, and ferritin, transferrin receptor (TfR), and the inflammatory biomarker, C-reactive protein (CRP) were measured in serum by NHANES study personnel. Serum and blood samples were collected at a single visit during the mobile examination phase of NHANES. A complete description of the protocol used in the collection of the iron and inflammatory biomarkers can be found online (<https://wwwn.cdc.gov/nchs/nhanes/default.aspx>).

Serum ferritin ^{24,25} and TfR ^{26,27} were analyzed using the immunoturbidimetric assay method via Roche kits on a Hitachi 912 clinical analyzer for 1999-2008 samples, and on an Elecsys 170 for ferritin, ²⁸ and Hitachi Mod P for TfR ²⁹ for the 2009-2010 samples. Due to the use of different technologies for assessment and following best-practice, we standardized ferritin concentrations using the formula, $10^{(0.989 \cdot \log_{10}(\text{Hitachi 912}) + 0.049)}$ (https://wwwn.cdc.gov/Nchs/Nhanes/2009-2010/TFR_F.htm). We calculated total body iron as $[\log_{10}(\text{TfR}_{\text{Cook}} \cdot 1000 / \text{adjusted Ferritin}) - 2.8229]$ where $\text{TfR}_{\text{Cook}} = 1.5 \cdot \text{unadjusted TfR}_{\text{Roche}} + 0.35$ to match Cook's standard values ³⁰. We used the total body iron cutoff < 0 mg/kg to classify ID ³⁰. We also defined ID as ferritin < 12 $\mu\text{g/L}$ ³¹ and TfR > 4.4 mg/L ³². NHANES measured Hb as part of the complete blood count analysis using a quantitative cell counter (^{33,34} Beckman Coulter, Brea, CA). We defined anemia as Hb < 11 g/dL, per Centers for Disease Control and Prevention guidelines ³¹. The American College of Obstetricians and Gynecologists suggests

using a different cutoff ($Hb < 10.5$ g/dL) for anemia during 2nd trimester³⁵. However, we chose to use a single cutoff due to the difficulty of classifying a large number of participants with ‘unknown’ or missing trimester data ($n=183$). Instead, we have included trimester as a covariate in all adjusted models. CRP was assessed with latex-enhanced nephelometry by NHANES^{36–38} (Dade Behring Inc, Deerfield, IL). We defined inflammation as $CRP > 5$ mg/L³⁹. Ferritin is an acute phase protein and therefore can change in response to inflammation. It is recommended to adjust ferritin for inflammation with CRP and alpha(1)-acid glycoprotein using the BRINDA method in this population^{40,41}. However, NHANES did not measure alpha(1)-acid glycoprotein in the cycles we included. In addition, a linear relationship was not observed between log-transformed ferritin and log-transformed CRP, suggesting that the BRINDA method was not appropriate for this data⁴². Therefore, we did not adjust ferritin for inflammation, similar to the approach taken by previous studies⁹. IDA was defined as anemia and ID using each iron indicator separately (ferritin, TfR, and total body iron)⁴³.

Body mass index

We calculated pre-pregnancy BMI (kg/m^2) based on pre-pregnancy weight (self-reported) and height (measured to the nearest mm in the Mobile Examination Center). We used the following BMI categories developed by the World Health Organization: underweight (< 18.5 kg/m^2), normal ($18.5-24.9$ kg/m^2), overweight ($25-29.9$ kg/m^2), and obese (≥ 30 kg/m^2)⁴⁴.

Covariates

Maternal and household characteristics were collected via demographic and reproductive questionnaires. Based on prior literature^{7,9,11,45}, we identified maternal age, race/ethnicity, maternal education, family income (NHANES calculated as poverty:income ratio)⁴⁶, and

pregnancy trimester as confounders for inclusion as covariates in our models. Parity was considered but was not included due to high amounts of missing data (approximately 30%).

Maternal age and self-reported race/ethnicity variables did not have missing data. The maternal age variable was used as continuous in the analyses. The race/ethnicity variable was used as a categorical variable based on the NHANES created levels, Mexican American, Other Hispanic, non-Hispanic White, non-Hispanic Black, and Other Race – Including Multi-Racial. The ‘Other’ race category included participants selecting from various Asian, Pacific Islander, and Native American categories, as well as those selecting multiple races. NHANES cycles from 1999-2006 oversampled Mexican-American ethnicity, and therefore estimates for Hispanic ethnicity from those cycles represent primarily Mexican-American ethnicity (<https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/99-10-analytic-guidelines.pdf>). Due to small sample size in our current study, we combined the Mexican-American and Other Hispanic categories into one Hispanic category. However, it should be noted that the Hispanic category reliably represents only Mexican-American ethnicity from 1999-2006 (48).

There was one participant missing maternal education data, and this observation was collapsed with the high school diploma or less category, resulting in the final category of ‘high school diploma or less/unknown.’ Final maternal education categories were: high school diploma or less/unknown, some college, and college graduate. There were eighty-nine participants with missing family income data. These participants were coded as a separate unknown category. The final income categories were: poverty:income ratio < 130%, poverty:income ratio ≥ 130 , and unknown. Gestational age was self-reported as months in NHANES, and we used this information to categorize participants as first trimester (0-3 months), second trimester (4-6 months), and third trimester (7-9 months). Participants who did not know their gestational age or

did not know they were pregnant were coded as unknown (n = 178). There were five participants missing gestational age data, and these observations were collapsed with participants who reported an unknown gestational age. Final trimester categories were: first trimester, second trimester, third trimester, and unknown.

Statistical analysis

All data were analyzed using weighted statistics in SAS version 9.4 (Cary, NC) and Stata version 18 (College Station, TX), as recommended by the NHANES website (<https://www.cdc.gov/nchs/nhanes/index.htm>). Data merging, cleaning, and descriptive statistics were performed in SAS, while adjusted models were performed in Stata. Survey methods were used in both SAS and Stata to account for the complex sampling design of the NHANES survey, including strata, cluster, and mobile examination center weights.

Descriptive statistics, including percentages and standard errors, were conducted in the total sample and by the outcomes of interest, ID, anemia, and IDA, using weighted Chi-square tests. For our primary analysis, ferritin, TfR, total body iron, and Hb were assessed by BMI category and by continuous BMI. The iron biomarkers ferritin and TfR did not follow a normal distribution, and thus were log transformed for analyses. Total body iron and Hb followed a normal distribution and were not transformed. Associations between iron biomarker concentrations and BMI (both continuous and categorical) were tested using weighted multiple linear regression models adjusted for age, race/ethnicity, education level, family income, and trimester of pregnancy. When analyzing BMI as a categorical variable, the Bonferroni adjustment for multiple comparisons was used when performing pairwise comparisons. Prevalence ratios and prevalence differences of ID, anemia, and IDA with their respective

confidence intervals were calculated by BMI category using Poisson regression models with robust error variance.

All Poisson regression models calculating prevalence were performed with and without covariates. Covariates included in all models were: age, race/ethnicity, education level, family income, and trimester of pregnancy. If the number of cases was < 30 for any model, then the estimates for those analyses were deemed unreliable and have been noted in the results⁴⁷.

Statistical significance was defined as $p < 0.05$ for all models.

Results

Overall Population Characteristics

The mean (standard error) age for the pregnant women in this study was 28.0 (0.29) years. Sample characteristics are reported in the total sample and by ID (based on total body iron), anemia (based on Hb), and IDA (based on total body iron and Hb) in Table 1. Approximately 30% of women graduated from college and 24% had a family income below 130% of the poverty to income ratio. Overall, approximately half of the sample size had a normal pre-pregnancy BMI and were of non-Hispanic White race/ethnicity. The prevalence of ID (based on total body iron), anemia, and IDA (based on total body iron and Hb) were 14%, 8%, and 3%, respectively, and the prevalence of inflammation was 48% (S1 Table). The prevalence of ID, anemia, and IDA were similar across most characteristics but were all highest during the third trimester and among non-Hispanic Black women.

Table 1: Characteristics of pregnant women (18-49 years of age) from NHANES 1999-2010 for the total sample, by iron deficiency, anemia, and iron deficiency anemia.

Variables	Total Sample N=1156		Iron Deficiency ^a N=211		Anemia ^b N=100		IDA ^c N=49	
	N ^d	% (SE) ^e	N (cases)	% (SE)	N (cases)	% (SE)	N (cases)	% (SE)
Age groups								
18-24	428	31.7 (1.88)	100	17.6 (3.14)	36	7.65 (2.16)	21	4.12 (1.59)
25-29	352	28.7 (1.81)	66	16.4 (3.16)	34	7.36 (1.90)	16	2.47 (0.88)
30-34	258	23.2 (2.02)	34	14.3 (3.75)	19	7.40 (2.45)	7	2.14 (1.10)
35-49	118	16.4 (2.41)	11	3.44 (1.31)	11	7.88 (3.36)	5	1.43 (0.71)
Overall p-value				0.03		1.00		0.31
Race/Ethnicity								
Hispanic	401	22.3 (2.00)	89	17.5 (2.56)	38	8.35 (2.05)	21	3.07 (0.91)
NH White	512	53.2 (3.03)	72	10.6 (1.99)	25	3.28 (1.29)	14	1.66 (0.93)
NH Black	170	14.5 (1.89)	39	23.3 (4.30)	30	18.5 (3.81)	12	7.67 (2.85)
NH Other	73	9.97 (1.96)	11	12.7 (6.94)	7	12.7 (6.01)	2	0.64 (0.47)
Overall p-value				0.09		< 0.001		0.01
Education								
HS diploma or less/unknown	597	41.3 (2.45)	123	16.3 (2.09)	58	8.70 (1.77)	29	2.87 (0.74)
Some college	305	28.9 (2.37)	70	21.3 (3.95)	29	8.43 (2.35)	17	4.99 (2.00)
College graduate	254	29.9 (2.54)	18	4.33 (2.44)	13	5.11 (2.11)	3	0.41 (0.24)
Overall p-value				0.007		0.41		0.004
Family income (poverty:income ratio)								
< 130%	365	24.2 (1.90)	73	15.1 (2.35)	40	10.2 (1.92)	18	3.91 (1.17)
≥ 130%	702	68.0 (2.10)	116	13.5 (1.70)	52	6.68 (1.54)	27	2.44 (0.83)
Unknown/missing	89	7.80 (1.19)	22	16.5 (4.63)	8	7.07 (3.65)	4	1.83 (1.14)
Overall p-value				0.72		0.33		0.35
Pregnancy trimester								

First (0-3)	178	19.2 (1.88)	9	2.65 (1.23)	5	2.09 (1.18)	2	0.98 (0.87)
Second (4-6)	406	30.1 (2.20)	55	11.2 (2.21)	31	6.86 (1.84)	16	2.36 (0.84)
Third (7-10)	389	30.9 (2.21)	111	23.7 (3.24)	48	11.7 (2.83)	25	4.07 (1.63)
Unknown/missing	183	19.9 (1.94)	36	15.0 (4.33)	16	7.40 (2.21)	6	2.98 (1.50)
Overall p-value				< 0.001		0.02		0.38
Pre-pregnancy BMI (kg/m²)								
Underweight, <18.5	66	5.35 (1.05)	17	12.1 (4.56)	7	5.14 (2.48)	6	4.41 (2.33)
Normal, 18.5-24.9	609	52.4 (2.15)	113	13.8 (2.10)	53	7.05 (1.70)	30	3.20 (1.04)
Overweight, 25.0-29.9	265	21.7 (1.74)	49	18.5 (3.12)	23	8.81 (2.48)	9	2.63 (1.25)
Obese ≥30.0	216	20.5 (1.87)	32	10.7 (3.02)	17	8.11 (2.71)	4	1.28 (0.85)
Overall p-value				0.31		0.82		0.48

^a Iron deficiency was defined based on total body iron < 0 mg/kg. Total body iron was calculated using ferritin and transferrin receptor using Cook's equation ³⁰.

^b Anemia was defined based on hemoglobin < 11 g/dL.

^c IDA was defined as both total body iron < 0 mg/kg and hemoglobin < 11 g/dL.

^d N values were non-weighted.

^e Percentages and standard errors for all columns were weighted and analyzed using chi-square tests.

Abbreviations: BMI=Body mass index; HS=High school; IDA=Iron deficiency anemia; NH=Non-Hispanic; SE=Standard error.

Iron Status by BMI Category

Ferritin and total body iron concentrations were slightly lower in women with pre-pregnancy BMI in the normal and overweight categories compared to the underweight and obese categories, but these differences have very low confidence ($p > 0.10$; Fig 1). There were also no statistical or meaningful differences between BMI groups in TfR or Hb. We tested if continuous pre-pregnancy BMI (kg/m^2) was associated with concentrations of iron biomarkers (ferritin, TfR, total body iron, and Hb), and we found no association in unadjusted or adjusted models ($p > 0.10$; results not shown).

Fig 1. Iron status biomarker concentrations by BMI category (n=1156). Serum concentrations of: A) Ferritin ($p = 0.11$), B) TfR ($p = 0.70$), C) Total Body Iron ($p = 0.13$), and D) Hb ($p = 0.74$) stratified by BMI categories (Underweight, $< 18.5 \text{ kg/m}^2$; Normal, $18.5\text{-}24.9 \text{ kg/m}^2$; Overweight, $25\text{-}29.9 \text{ kg/m}^2$; Obesity, $\geq 30 \text{ kg/m}^2$). Data are presented as adjusted least squares means \pm 95% confidence intervals ($1.96 \times$ standard errors of the means). Differences between groups were assessed using weighted multiple linear regression models adjusted for age, race/ethnicity, education level, family income (PIR), and trimester of pregnancy and adjusted for multiple comparisons using the Bonferroni method. Ferritin and transferrin receptor (TfR) were log-transformed in the models to account for non-normal distributions. Means and confidence intervals were exponentiated for presentation. Total body iron was calculated using Ferritin and transferrin receptor using Cook's equation³⁰. Abbreviations: BMI=Body mass index (kg/m^2); Ferritin=Ferritin; Hb=Hemoglobin; PIR=Poverty:income ratio; TfR=Transferrin receptor.

230 Similarly, we found no differences in the prevalence of ID (total body iron < 0 mg/kg),
231 anemia (Hb < 11 g/dL), or IDA by pre-pregnancy BMI (Table 2). However, because the number
232 of IDA cases was low within each BMI category, the estimates in adjusted models should be
233 considered unreliable and interpreted with caution. The number of cases for all outcomes was
234 also low in the underweight (BMI < 18.5 kg/m²) category.

235 **Table 2: Weighted prevalences and prevalence ratios and differences of iron deficiency and anemia status in pregnant women**
 236 **ages 18-49 by pre-pregnancy BMI from NHANES 1999-2010 (n = 1156).**

Pre-pregnancy BMI categories by iron status:	Prevalence [% (Standard Error)]	Cases (N) ^a	Unadjusted Prevalence Ratio (95% CI) ^b	Adjusted Prevalence Ratio (95% CI) ^c	Adjusted Prevalence Difference [excess cases per 100 (95% CI)]
ID (Ferritin < 12 ug/L)					
Underweight BMI, < 18.5	15.5 (5.31)	18	0.75 (0.37, 1.52) ^d	0.78 (0.39, 1.57) ^d	-4.51 (-16.3, 7.25) ^d
Normal BMI, 18.5-24.9	20.6 (2.78)	156	Reference	Reference	Reference
Overweight BMI, 25-29.9	21.2 (4.18)	64	1.03 (0.64, 1.64)	0.98 (0.64, 1.51)	-0.43 (-9.32, 8.46)
Obese BMI, ≥ 30	15.5 (4.06)	38	0.75 (0.41, 1.38)	0.72 (0.41, 1.27)	-5.79 (-15.1, 3.53)
ID (TfR > 4.4 mg/L)					
Underweight BMI, < 18.5	12.5 (4.35)	16	0.72 (0.34, 1.49) ^d	0.97 (0.49, 1.93) ^d	-0.53 (-11.6, 10.6) ^d
Normal BMI, 18.5-24.9	17.4 (2.54)	110	Reference	Reference	Reference
Overweight BMI, 25-29.9	17.5 (2.91)	46	1.01 (0.63, 1.62)	1.09 (0.72, 1.64)	1.42 (-5.77, 8.62)
Obese BMI, ≥ 30	14.7 (3.26)	40	0.85 (0.52, 1.39)	0.93 (0.61, 1.41)	-1.24 (-7.90, 5.42)
ID (Total body iron < 0 mg/kg)^e					
Underweight BMI, < 18.5	12.7 (4.56)	17	0.91 (0.43, 1.92) ^d	0.88 (0.41, 1.89) ^d	-1.74 (-11.4, 7.94) ^d
Normal BMI, 18.5-24.9	13.9 (2.10)	113	Reference	Reference	Reference
Overweight BMI, 25-29.9	18.5 (3.12)	49	1.33 (0.86, 2.05)	1.27 (0.89, 1.82)	3.88 (-1.95, 9.70)
Obese BMI, ≥ 30	10.7 (3.02)	32	0.77 (0.40, 1.49)	0.75 (0.39, 1.45)	-3.49 (-11.0, 4.06)
Anemia (Hb < 11 g/dL)^f					
Underweight BMI, < 18.5	5.14 (2.48)	7	0.73 (0.25, 2.13) ^d	0.88 (0.28, 2.77) ^d	-0.90 (-8.57, 6.77) ^d
Normal BMI, 18.5-24.9	7.05 (1.70)	53	Reference	Reference	Reference
Overweight BMI, 25-29.9	8.81 (2.48)	23	1.25 (0.61, 2.55)	1.08 (0.53, 2.19)	0.58 (-4.98, 6.14)
Obese BMI, ≥ 30	8.11 (2.71)	17	1.15 (0.55, 2.43)	0.99 (0.49, 2.01)	-0.05 (-5.29, 5.19)
ID Anemia (Hb < 11 g/dL and Total body iron < 0 mg/kg)^f					
Underweight BMI, < 18.5	4.41 (2.33)	6	1.38 (0.40, 4.71) ^d	1.38 (0.39, 4.90) ^d	1.44 (-4.84, 7.72) ^d
Normal BMI, 18.5-24.9	3.20 (1.04)	30	Reference	Reference	Reference
Overweight BMI, 25-29.9	2.63 (1.25)	9	0.82 (0.29, 2.35)	0.62 (0.24, 1.57)	-1.44 (-4.01, 1.14)
Obese BMI, ≥ 30	1.28 (0.85)	4	0.40 (0.09, 1.70)	0.27 (0.08, 0.89)	-2.75 (-5.05, -0.44)

237 ^a N values represent non-weighted number of cases; all other analyses were weighted.

238 ^b Prevalence ratios and differences were calculated using Poisson regression models with robust error variance.

239 ^c The covariates included in all adjusted models were age, race/ethnicity, education level, family income, and trimester of pregnancy.
240 ^d Estimates for the underweight BMI (< 18 kg/m²) group may be unreliable because the number of cases was < 30 for all models ⁴⁷.
241 ^e Total body iron was calculated using ferritin and transferrin receptor using Cook's equation ³⁰.
242 ^f Estimates may be unreliable due to sample size of cases < 30 for some BMI categories ⁴⁷.
243 Abbreviations: BMI=Body mass index; CI=Confidence interval; Ferritin=Ferritin; ID=Iron deficiency; IDA=Iron deficiency anemia;
244 Hb=Hemoglobin; TfR=Transferrin receptor

Discussion

Based on NHANES data from 1999-2010, pre-pregnancy overweight and obesity were not associated with increased prevalence of ID or anemia during pregnancy in this US population. Although pre-pregnancy obesity is strongly linked to increased risk of adverse pregnancy outcomes, based on our results, it was not associated with ID or anemia.

To our knowledge, the association between iron status and BMI has not been examined with nationally representative data in US pregnant women using biomarkers of either the circulating iron or storage iron components. The circulating iron component is measured with biomarkers such as TfR, serum iron, or transferrin saturation. Two prior cross-sectional cohort studies conducted in the US observed no association between circulating iron biomarkers and BMI groups^{17,18}, which is similar to our findings. Of note, one of these studies¹⁸ was conducted in adolescents (13-18 years of age) and the other¹⁷ was limited by a small sample size (n=15 per group). Interestingly, studies from outside of the US have found contradictory results with some finding no association between TfR and obesity^{19,22,48} and others observing that TfR concentrations were higher (indicating poorer iron status) in women with obesity^{19-21,49}.

Our results for the storage iron component, measured by ferritin, are largely consistent with other studies^{20,21,49}. However, one study¹⁸ found that higher concentrations of ferritin at mid-gestation and delivery were associated with classes two and three of obesity (BMI 35-39.9 and ≥ 40 kg/m²) compared with normal pre-pregnancy BMI. In the current study, we did not have a large enough sample size to stratify by obesity class. In addition, although NHANES recorded trimester at the time of assessment for each pregnant participant, there was not a large enough sample size to test for interactions between BMI category and trimester in the current study.

In addition to its function as an iron storage biomarker, ferritin is an acute phase protein, susceptible to inflammation, measured by CRP in the NHANES study. The prevalence of inflammation based on CRP >5 mg/L in our sample was 48%, which is similar to results reported by Mei et al. ⁹. Previous studies have observed higher concentrations of inflammatory markers such as CRP, interleukin-6, leptin, and hepcidin in women with obesity compared with normal weight ^{18,20}. In our study, pregnant women with obesity had significantly higher concentrations of the inflammatory protein, CRP, (mean (standard error) = 13.2 (1.5) mg/L) than other BMI categories (mean (standard error) = 6.6 (0.6) mg/L; $p < 0.001$), suggesting that elevated serum CRP is more strongly related to obesity in this sample than with acute inflammatory response. Others have found that chronic inflammation may be connected to lower ferritin concentrations through the regulatory hormone hepcidin. Hepcidin increases when iron concentrations in circulation are adequate or in the presence of inflammation ⁵⁰ and acts by blocking iron release from storage into circulation via degradation of the efflux protein, ferroportin ⁵¹. This would suggest that obesity-related inflammation would lead to lower circulating ferritin concentrations, which was not supported by our findings. However, our results may be explained by the fact that hepcidin rises only moderately in individuals with obesity when compared to those with serious inflammatory diseases ⁵⁰. Testing this mechanism was outside the scope of our study, since NHANES has not measured hepcidin in laboratory measures. Last, the functional iron compartment, measured with Hb, was not associated with BMI categories in our sample, which is consistent with prior studies ^{18,19,21,22}.

Overall, we did not find any meaningful association with iron status biomarkers and BMI when adjusting for age, race/ethnicity, education level, family income, and trimester of pregnancy. Although our results differed from other studies, there could be a variety of factors

explaining these differences. First, distinct populations may have different associations between BMI and ID, and studies conducted in other countries may be measuring completely different populations. Second, there may be other unmeasured confounding factors such as access to medical care and food security status. For instance, access to medical care during pregnancy may delay diagnosis of ID and anemia and in turn, prescription of iron supplements during critical stages of pregnancy when it is needed most, and that pregnant women with food insecurity are more likely to have both lower iron intake and iron deficiency ⁵². Last, prenatal iron supplementation could also be a contributing factor to iron status. Analyses of NHANES data from 1996 to 2006 ⁵³ show that 77% of pregnant women self-reported taking a supplement containing iron (48 mg) in the previous 30 days, but previous studies have also found lower supplement use and iron intake in non-Hispanic Black pregnant women ^{54,55}. Our work focused on iron status (concentrations and prevalences) rather than dietary sources such as iron supplementation, but based on prior evidence, we may infer that the majority of pregnant women in our analysis took an iron supplement during pregnancy.

The prevalence of ID in this study, based on total body iron, was 14%, which was similar to ID prevalence (also based on total body iron) observed in the Gupta et al., (16%) ⁷, and Mei et al., (18%) ⁹, both previous NHANES studies. The prevalence of anemia in our study was 8%, which was similar to the prevalence of 5% found by Mei et al. ⁹. Our estimate of IDA was also similar to the 3% reported by Gupta et al. ⁷. Slight discrepancies in prevalence rates between these studies may be explained by differing NHANES cycles included in analysis and differing age ranges. In the study by Gupta et al., the same cycles were used, but the age range (12-49 yrs.) was wider. The study by Mei et al. used fewer NHANES cycles (1999-2006) and included women aged 15-39 yrs. Overall, NHANES studies, including our current study, have observed

that prevalence of ID is higher than prevalence of anemia and IDA. Total anemia prevalence (5-8%) in pregnant women is low in the US, compared with the global prevalence of 37%⁵⁶.

Strengths & Limitations

This study's main strength is that it uses a nationally representative sample of US pregnant women. Further, NHANES oversampled pregnant women during the 1999-2006 cycles and used comprehensive methods to assess iron status including the total body iron indicator. Our study has, however, some limitations. First, the cross-sectional design precludes establishing a temporal relationship. Second, as in any observational study, residual confounding may be present despite our effort to adjust our models, particularly due to not being able to include parity. Third, pre-pregnancy weight was self-reported, which may misclassify maternal BMI. Fourth, due to the cross-sectional nature of the survey, we were unable to calculate gestational weight gain, which would have been more accurate in testing its association with iron status. Another potential confounder is gestational diabetes, which is only collected in two out of the six cycles included in this analysis, thus, we were unable to account for this factor. Fifth, the most recent iron status biomarker data combined with full pregnancy data (trimester or gestational age) in NHANES is over ten years old, and there is some evidence that it may overestimate the prevalence of anemia in low-income women⁵⁷. Therefore, it is unknown whether these data are representative of the current population. NHANES should consider future collection of both iron status biomarkers and all variables needed to assess iron status during pregnancy. Last, the number of cases of anemia and especially of IDA was small in the overall sample and even smaller when stratified by BMI groups, making adjusted prevalence estimates less reliable and requiring caution for interpretation.

Conclusions

Overweight and obesity are common, and the prevalence continues to rise in pregnant women in the US. However, using the NHANES 1999-2010 cycles, we did not find women with pre-pregnancy overweight or obesity to have an increased likelihood for ID or anemia during pregnancy when compared to pre-pregnancy normal weight. Previous studies reporting an association between BMI and iron status were conducted in different populations and may have been confounded by other demographic factors. Given these results and the fact that prenatal iron deficiency remains a significant public health concern, there is a need to continue collection of high-quality national data on these biomarkers during pregnancy to assess progress over time in alleviating maternal health disparities.

Acknowledgements

The authors would like to acknowledge the contribution of Elizabeth Soucy, who assisted with the initial literature search for this project.

References

1. Sundararajan S, Rabe H. Prevention of iron deficiency anemia in infants and toddlers. *Pediatric Research*. 2021;89(1):63–73. PMID: 32330927
2. Scholl TO. Maternal iron status: Relation to fetal growth, length of gestation, and iron endowment of the neonate. *Nutrition Reviews*. 2011;69(SUPPL. 1):23–29. PMID: 22043878
3. Marchi J, Berg M, Dencker A, Olander EK, Begley C. Risks associated with obesity in pregnancy, for the mother and baby: A systematic review of reviews. *Obesity Reviews*. 2015;16(8):621–638. PMID: 26016557
4. Rasmussen KM. Association of maternal obesity before conception with poor lactation performance. *Annual review of nutrition*. 2007;27:103–121. PMID: 17341160
5. Pfeiffer CM, Sternberg MR, Caldwell KL, Pan Y. Race-Ethnicity Is Related to Biomarkers of Iron and Iodine Status after Adjusting for Sociodemographic and Lifestyle Variables in NHANES 2003–2006. *The Journal of Nutrition*. 2013 Jun 1;143(6):977S-985S.

- 364 6. Driscoll AK, Gregory ECW. Increases in Prepregnancy Obesity: United States, 2016-2019. NCHS data
365 brief. 2020;(392):1–8. PMID: 33270551
- 366 7. Gupta PM, Hamner HC, Suchdev PS, Flores-Ayala R, Mei Z. Iron status of toddlers, nonpregnant
367 females, and pregnant females in the United States. American Journal of Clinical Nutrition.
368 2017;106(1d):1640S-1646S. PMID: 29070559
- 369 8. Miller EM. Iron status and reproduction in US women: National health and nutrition examination
370 survey, 1999-2006. PLoS ONE. 2014;9(11):1999–2006. PMID: 25375360
- 371 9. Mei Z, Cogswell ME, Looker AC, Pfeiffer CM, Cusick SE, Lacher DA, Grummer-Strawn LM.
372 Assessment of iron status in US pregnant women from the national health and nutrition
373 examination survey (NHANES), 1999-2006. American Journal of Clinical Nutrition.
374 2011;93(6):1312–1320. PMID: 21430118
- 375 10. Milman N. Iron and pregnancy--a delicate balance. Ann Hematol. 2006 Sep;85(9):559–565. PMID:
376 16691399
- 377 11. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the
378 United States. Journal of the American Medical Association. 1997;277(12):973–976. PMID:
379 9091669
- 380 12. Brannon PM, Taylor CL. Iron supplementation during pregnancy and infancy: Uncertainties and
381 implications for research and policy. Nutrients. 2017;9(12):1–17. PMID: 29210994
- 382 13. Pobee RA, Setorglo J, Klevor M, Murray-Kolb LE. The prevalence of anemia and iron deficiency
383 among pregnant Ghanaian women, a longitudinal study. PLoS ONE. 2021;16(3 March):1–14. PMID:
384 33760869
- 385 14. Rockfield S, Chhabra R, Robertson M, Rehman N, Bisht R, Nanjundan M. Links between iron and
386 lipids: Implications in some major human diseases. Pharmaceuticals. 2018;11(4):1–14.
- 387 15. Cepeda-Lopez AC, Osendarp SJM, Melse-Boonstra A, Aeberli I, Gonzalez-Salazar F, Feskens E,
388 Villalpando S, Zimmermann MB. Sharply higher rates of iron deficiency in obese Mexican women
389 and children are predicted by obesity-related inflammation rather than by differences in dietary
390 iron intake. American Journal of Clinical Nutrition. 2011;93(5):975–983.
- 391 16. Wawer AA, Hodyl NA, Fairweather-Tait S, Froessler B. Are pregnant women who are living with
392 overweight or obesity at greater risk of developing iron deficiency/anaemia? Nutrients.
393 2021;13(5). PMID: 34067098
- 394 17. Dao MC, Sen S, Iyer C, Klebenov D, Meydani SN. Obesity during Pregnancy and Fetal Iron Status: is
395 Hepcidin the link? J Perinatol. 2013;33(3):177–181.
- 396 18. Cao C, Pressman EK, Cooper EM, Guillet R, Westerman M, O'Brien KO. Prepregnancy Body Mass
397 Index and Gestational Weight Gain Have No Negative Impact on Maternal or Neonatal Iron Status.
398 Reproductive Sciences. 2016;23(5):613–622. PMID: 26423600

- 399 19. Garcia-Valdes L, Campoy C, Hayes H, Florido J, Rusanova I, Miranda MT, McArdle HJ. The impact of
400 maternal obesity on iron status, placental transferrin receptor expression and hepcidin expression
401 in human pregnancy. *International Journal of Obesity*. Nature Publishing Group; 2015;39(4):571–
402 578. PMID: 25614087
- 403 20. Flynn AC, Begum S, White SL, Dalrymple K, Gill C, Alwan NA, Kiely M, Latunde-Dada G, Bell R, Briley
404 AL, Nelson SM, Oteng-Ntim E, Sandall J, Sanders TA, Whitworth M, Murray DM, Kenny LC, Poston
405 L. Relationships between maternal obesity and maternal and neonatal iron status. *Nutrients*.
406 2018;10(8):1–10. PMID: 30061547
- 407 21. Jones AD, Zhao G, Jiang YP, Zhou M, Xu G, Kaciroti N, Zhang Z, Lozoff B. Maternal obesity during
408 pregnancy is negatively associated with maternal and neonatal iron status. *Eur J Clin Nutr*. 2016
409 Jan 27; PMID: 26813939
- 410 22. Flores-Quijano ME, Vega-Sánchez R, Tolentino-Dolores MC, López-Alarcón MG, Flores-Urrutia MC,
411 López-Olvera AD, Talavera JO. Is associated with changes in iron nutrition status and its
412 homeostatic regulation in pregnancy. *Nutrients*. 2019;11(3):1–17. PMID: 30909605
- 413 23. NHANES - NCHS Research Ethics Review Board Approval [Internet]. National Center for Health
414 Statistics. 2019 [cited 2020 Dec 8]. Available from: <https://www.cdc.gov/nchs/nhanes/irba98.htm>
- 415 24. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2005-2006) [Internet]. National
416 Center for Health Statistics. 2008 [cited 2020 Dec 8]. Available from:
417 https://wwwn.cdc.gov/nchs/data/nhanes/2005-2006/labmethods/fertin_d_met_roche.pdf
- 418 25. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2007-2008) [Internet]. National
419 Center for Health Statistics. 2009. Available from: [https://wwwn.cdc.gov/nchs/data/nhanes/2007-](https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/fertin_e_met_ferritin.pdf)
420 [2008/labmethods/fertin_e_met_ferritin.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/fertin_e_met_ferritin.pdf)
- 421 26. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2005-2006)
422 [Internet]. National Center for Health Statistics. 2008. Available from:
423 https://www.cdc.gov/NCHS/data/nhanes/nhanes_05_06/tfr_d_met_transferrin_receptor.pdf
- 424 27. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2007-2008)
425 [Internet]. National Center for Health Statistics. 2009. Available from:
426 [https://wwwn.cdc.gov/nchs/data/nhanes/2007-](https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/tfr_e_met_transferrin_receptor.pdf)
427 [2008/labmethods/tfr_e_met_transferrin_receptor.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/tfr_e_met_transferrin_receptor.pdf)
- 428 28. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2009-2010) [Internet]. National
429 Center for Health Statistics. 2012. Available from: [https://wwwn.cdc.gov/nchs/data/nhanes/2009-](https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/fertin_f_met_ferritin.pdf)
430 [2010/labmethods/fertin_f_met_ferritin.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/fertin_f_met_ferritin.pdf)
- 431 29. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2009-2010)
432 [Internet]. National Center for Health Statistics. 2012. Available from:
433 [https://wwwn.cdc.gov/nchs/data/nhanes/2009-](https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/tfr_f_met_transferrin_receptor.pdf)
434 [2010/labmethods/tfr_f_met_transferrin_receptor.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/tfr_f_met_transferrin_receptor.pdf)
- 435 30. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. *Blood*. 2003 May
436 1;101(9):3359–3363. PMID: 12521995

31. Centers for Disease Control and Prevention. Recommendations to Prevent and Control Iron Deficiency in the United States [Internet]. 1998 Apr p. 1–36. Report No.: 47 (RR–3). Available from: <https://www.cdc.gov/mmwr/preview/mmwrhtml/00051880.htm>
32. Kolbe-Busch S, Lotz J, Hafner G, Blanckaert NJC, Claeys G, Togni G, Carlsen J, Röddiger R, Thomas L. Multicenter evaluation of a fully mechanized soluble transferrin receptor assay on the Hitachi and cobas integra analyzers. the determination of reference ranges. Clin Chem Lab Med. 2002 May;40(5):529–536. PMID: 12113300
33. CDC 1999-2000. Laboratory Procedure Manual. CBC with five-part differential NHANES 1999-2000 [Internet]. [cited 2023 Oct 24]. Available from: https://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/lab25_met_complete_blood_count.pdf
34. CDC 2007-2008. Laboratory Procedure Manual. CBC with five-part differential NHANES 2007-2008.
35. ACOG Practice Bulletin. Anemia in Pregnancy: ACOG Practice Bulletin, Number 233. Obstet Gynecol. 2021 Aug 1;138(2):e55–e64. PMID: 34293770
36. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2005-2006) [Internet]. National Center for Health Statistics. 2007. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2005-2006/labmethods/crp_d_met_protein.pdf
37. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2007-2008) [Internet]. National Center for Health Statistics. 2007. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/crp_e_met.pdf
38. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2009-2010) [Internet]. National Center for Health Statistics. 2011. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/crp_f_met.pdf
39. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, Blaabjerg O, Blirup-Jensen S, Carlström A, Petersen PH, Johnson AM, Milford-Ward A, Ritchie RF, Svendsen PJ, Whicher J. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem. 1996 Jun;34(6):517–520. PMID: 8831057
40. Namaste SM, Rohner F, Huang J, Bhushan NL, Flores-Ayala R, Kupka R, Mei Z, Rawat R, Williams AM, Raiten DJ, Northrop-Clewes CA, Suchdev PS. Adjusting ferritin concentrations for inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. Am J Clin Nutr. 2017 Jul;106(Suppl 1):359S-371S. PMCID: PMC5490647
41. Namaste SML, Ou J, Williams AM, Young MF, Yu EX, Suchdev PS. Adjusting iron and vitamin A status in settings of inflammation: a sensitivity analysis of the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) approach. The American Journal of Clinical Nutrition. 2020 Aug 1;112(Supplement_1):458S-467S.

- 474 42. Luo H, Geng J, Zeiler M, Nieckula E, Sandalinas F, Williams A, Young MF, Suchdev PS. A Practical
475 Guide to Adjust Micronutrient Biomarkers for Inflammation Using the BRINDA Method. J Nutr.
476 2023 Apr;153(4):1265–1272. PMCID: PMC10202121
- 477 43. Acharya S, Beard JL, Davidson FR, Davidsson L, Hertrampf ED, Jacobs M, Lynch SR, Stoltzfus RJ.
478 Why iron is important and what do do about it: a new perspective. Washington (DC), INACG
479 Secretariat; 2002 p. 1–50.
- 480 44. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert
481 Committee. World Health Organ Tech Rep Ser. 1995;854:1–452. PMID: 8594834
- 482 45. Mei Z, Addo OY, Jefferds ME, Sharma AJ, Flores-Ayala RC, Brittenham GM. Physiologically based
483 serum ferritin thresholds for iron deficiency in children and non-pregnant women: a US National
484 Health and Nutrition Examination Surveys (NHANES) serial cross-sectional study. The Lancet
485 Haematology. 2021 Aug;8(8):e572–e582.
- 486 46. U.S. Department of Agriculture, Food and Nutrition Service. WIC eligibility requirements | USDA-
487 FNS [Internet]. 2020 [cited 2019 Aug 23]. Available from: [https://www.fns.usda.gov/wic/wic-](https://www.fns.usda.gov/wic/wic-eligibility-requirements)
488 [eligibility-requirements](https://www.fns.usda.gov/wic/wic-eligibility-requirements)
- 489 47. Parker JD, Talih M, Malec DJ, Beresovsky V, Carroll M, Gonzalez JF, Hamilton BE, Ingram DD,
490 Kochanek K, McCarty F, Moriarity C, Shimizu I, Strashny A, Ward BW. National Center for Health
491 Statistics Data Presentation Standards for Proportions. Vital Health Stat 2. 2017 Aug;(175):1–22.
492 PMID: 30248016
- 493 48. Vega-Sánchez R, Tolentino-Dolores MC, Cerezo-Rodríguez B, Chehaibar-Besil G, Flores-Quijano ME.
494 Erythropoiesis and Red Cell Indices Undergo Adjustments during Pregnancy in Response to
495 Maternal Body Size but not Inflammation. Nutrients. Multidisciplinary Digital Publishing Institute;
496 2020 Apr;12(4):975.
- 497 49. Flores-Quijano ME, Montalvo-Velarde I, Vital-Reyes VS, Rodríguez-Cruz M, Rendón-Macías ME,
498 López-Alarcón M. Longitudinal Analysis of the Interaction Between Obesity and Pregnancy on Iron
499 Homeostasis: Role of Hepcidin. Arch Med Res. 2016 Oct;47(7):550–556. PMID: 28262197
- 500 50. Tussing-Humphreys L, Pustacioglu C, Nemeth E, Braunschweig C. Rethinking Iron Regulation and
501 Assessment in Iron Deficiency, Anemia of Chronic Disease, and Obesity: Introducing Hepcidin. J
502 Acad Nutr Diet. 2012 Mar;112(3):391–400. PMCID: PMC3381289
- 503 51. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin
504 Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science.
505 2004 Dec 17;306(5704):2090–2093. PMID: 15514116
- 506 52. Park CY, Eicher-Miller HA. Iron deficiency is associated with food insecurity in pregnant females in
507 the United States: National Health and Nutrition Examination Survey 1999-2010. Journal of the
508 Academy of Nutrition and Dietetics. 2014 Dec 1;114(12):1967–1973.
- 509 53. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the
510 United States. J Nutr. 2013 Apr;143(4):486–492. PMCID: PMC4745881

511 54. Cogswell ME, Kettel-Khan L, Ramakrishnan U. Iron Supplement Use among Women in the United
512 States: Science, Policy and Practice. J Nutr. 2003 Jun 1;133(6):1974S-1977S.

513 55. Liu J, Zhu X, Fulda KG, Chen S, Tao MH. Comparison of Dietary Micronutrient Intakes by Body
514 Weight Status among Mexican-American and Non-Hispanic Black Women Aged 19–39 Years: An
515 Analysis of NHANES 2003–2014. Nutrients. Multidisciplinary Digital Publishing Institute; 2019
516 Dec;11(12):2846.

517 56. WHO. Anaemia in women and children [Internet]. World Health Organization. 2021 [cited 2023
518 Aug 12]. Available from:
519 https://www.who.int/data/gho/data/themes/topics/anaemia_in_women_and_children

520 57. Kanu FA, Hamner HC, Scanlon KS, Sharma AJ. Anemia Among Pregnant Women Participating in the
521 Special Supplemental Nutrition Program for Women, Infants, and Children - United States, 2008-
522 2018. MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):813–819. PMID: 35737575

523

524

Supporting Information

S1 Table: Weighted medians and prevalences of inflammation, iron, and anemia biomarkers in pregnant women of reproductive age (18-49 years of age) from the NHANES (1999-2010) study (n=1156).

S2 Table: Weighted prevalences and prevalence ratios and differences of iron deficiency and anemia status in pregnant women ages 18-49 by race/ethnicity from NHANES 1999-2010 (n = 1156).

S3 Table: Weighted prevalences and prevalence ratios and differences of iron deficiency and anemia status in pregnant women ages 18-49, by race/ethnicity from NHANES 1999-2010 (n=1156) using Mexican American and Hispanic Other categories.




Figure 1